Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: Results from a phase II trial

BJU International

Volumn 107, Issue 4, 2011, Pages 562-570

  Garcia, Jorge A ^a   Mekhail, Tarek ^a   Elson, Paul ^a   Triozzi, Pierre ^a   Nemec, Cheryl ^a   Dreicer, Robert ^a   Bukowski, Ronald M ^a   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

bevacizumab; immunomodulatory; low dose interleukin 2; phase II

Indexed keywords

BEVACIZUMAB; CD1C ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; TRANSCRIPTION FACTOR FOXP3;

ADRENAL METASTASIS; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HOARSENESS; HUMAN; HYPERTENSION; IMMUNOMODULATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NOSE CONGESTION; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; REGULATORY T LYMPHOCYTE; RETROPERITONEAL CANCER; SURVIVAL TIME; TASTE DISORDER; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOMODULATION; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 79551541309     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09573.x     Document Type: Article

References (44)

1. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-7
2. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-67
3. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-8
5. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
6. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-32
7. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-41
8. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410-1
9. Dvorak HF,. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80
10. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24
13. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11
14. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 33: 5422-8
15. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-41
16. Rayman P, Wesa AK, Richmond AL, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004; 10: 6360S-6S
17. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56: 1743-53
18. Gigante M, Blasi A, Loverre A, et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2009; 46: 893-901
19. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14: 5884-92
20. Sanarico N, Ciaramella A, Sacchi A, et al. Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J Leukoc Biol 2006; 80: 555-62
21. + regulatory T cells in cancer patients. Blood 2006; 107: 2409-14
22. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-103
23. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, SN M,. Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009; 15: 1931-9
24. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-32
25. Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12: 6808-16
26. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP,. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-70
27. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009; 27: 2645-52
28. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108: 51-62
29. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16
31. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110 (3): 543-50
32. van der Vliet HJ, Koon HB, Yue SC, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 2007; 13: 2100-8
33. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000; 96: 3499-504
34. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS,. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54: 99-105
35. Chakraborty A, Li L, Chakraborty NG, Mukherji B,. Stimulatory and inhibitory maturation of human macrophage-derived dendritic cells. Pathobiology 1999; 67: 282-6
36. Yang JS, Xu LY, Huang YM, Van Der Meide PH, Link H, Xiao BG,. Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis. Immunology 2000; 101: 397-403
37. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-77
38. + regulatory T cells. J Dermatol Sci 2009; 54: 69-75
39. Finke JH, Rini B, Ireland J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-57
40. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69 (6): 2514-22
41. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004; 2: 17
42. Engelhardt M, Wirth K, Mertelsmann R, Lindemann A, Brennscheidt U,. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2. Eur J Cancer 1997; 3: 1050-4
43. Piccioli D, Tavarini S, Borgogni E, et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007; 109: 5371-9
44. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G,. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007; 5: 51